Statistical Solutions: Visual Inspection Goes Viral - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Statistical Solutions: Visual Inspection Goes Viral
To properly inspect based on measurement, a reference standard is crucial for comparison.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 34-35

Inspection in action

Consider, for example, a manufacturing company that was using an industry standard 100% visual-inspection program to review finished vials. The program had been in place for several years and results of the visual inspections for spots on stoppers had typically been in the 2–5% range. However, over the course of several weeks, the cull rate escalated from 5% to more than 20%.

Alarmed, the quality unit conducted an investigation, but was unable to identify a clear reason for the dramatic increase. The inspectors and environment had not changed. Puzzled, the company brought in a consultant to assist with the investigation.

The consultant pointed out a fundamental measurement rule and asked, "Where is the standard for spots on stoppers?" The reply was, "There is none. Each inspector uses their best judgment." The consultant responded, "Without a standard, there is no basis for measurement."

Essentially, each inspector was using his own floating scale without any reference point. As the inspection continued, one inspector pointed out that he found a few more spots on the vials than usual. Sensitized to this information, the other inspectors became more vigilant and began to find more spots themselves. As word spread, the inspectors became hypersensitive, finding more and more spots as each lot was inspected until they were identifying more than 20% rejects.

Some identified spots were so small that the supervisors and managers could not see them even when pointed out by the inspectors. Without a standard for reference, any perceptible dot became a defect. A team discussion led to a defined specification: a spot below a certain size was not to be counted as a defect.

Summary

The company described in the above example soon adopted the TAPPT dirt estimation chart (1) as its reference standard. Each operator was given an original card for use during inspection. If any questions arose, the inspectors could compare potential defect spots to the chart and also review them with the supervisor.

Within one working shift, the defect level for spots on stoppers dropped back to the 2–5% range. The lesson learned: measurement is a comparison to a reference standard.

Lynn D. Torbeck is a statistician at Torbeck and Assoc., 2000 Dempster Plaza, Evanston, IL 60202, tel. 847.424.1314,
, http://www.torbeck.org/.

Reference

1. Dirt and Size Estimation Charts, http://www.tappi.org/Standards-TIPs/Dirt-Size-Charts.aspx, accessed Aug. 19, 2010.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here